journal
MENU ▼
Read by QxMD icon Read
search

Clinical Advances in Hematology & Oncology: H&O

journal
https://www.readbyqxmd.com/read/30148829/the-evolving-role-of-transplantation-in-multiple-myeloma-the-need-for-a-heterogeneous-approach-to-a-heterogeneous-disease
#1
Sara Gandolfi, Carolyn Vekstein, Jacob P Laubach, Alexandra O'Brien, Kelly Masone, Nikhil C Munshi, Kenneth C Anderson, Paul G Richardson
Autologous stem cell transplant (ASCT) is an established frontline standard of care for the younger, fitter patients with newly diagnosed multiple myeloma (NDMM) who are eligible for the procedure, and has contributed to improved overall survival. In the current era of novel therapies, the treatment landscape and prognosis have changed. The outstanding efficacy seen with regimens based on novel agents has led to a questioning of the frontline treatment paradigm with respect to ASCT. A key current question is whether to use transplant early or to collect stem cells early but save ASCT for salvage therapy...
August 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30148828/adjuvant-treatment-in-renal-cell-carcinoma
#2
Nazli Dizman, Jacob J Adashek, JoAnn Hsu, Paulo G Bergerot, Cristiane D Bergerot, Sumanta K Pal
In parallel with advances in the treatment of metastatic renal cell carcinoma (RCC), multiple adjuvant treatments have been tested for RCC. Adjuvant approaches now extend beyond conventional immunotherapies, such as interferon alfa and interleukins, to targeted therapies and immune checkpoint inhibitors. Most treatment approaches before the targeted treatment era did not improve patient outcomes, or study results were mixed. For example, a recent study found that disease-free survival was longer with sunitinib than with placebo in high-risk clear cell RCC, which led to the regulatory approval of sunitinib...
August 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30148827/chemoprevention-of-colorectal-cancer-aspirin-and-beyond
#3
Paul J Limburg
No abstract text is available yet for this article.
August 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30148826/weight-based-dosing-vs-fixed-dosing-of-pembrolizumab-an-economic-analysis
#4
Daniel Goldstein
No abstract text is available yet for this article.
August 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30148825/immunotherapy-in-the-adjuvant-setting-for-high-risk-melanoma
#5
Jeffrey S Weber
No abstract text is available yet for this article.
August 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30148824/highlights-in-breast-cancer-from-the-2018-american-society-of-clinical-oncology-annual-meeting
#6
Hope S Rugo
No abstract text is available yet for this article.
August 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30235180/highlights-in-chronic-lymphocytic-leukemia-from-the-2018-american-society-of-clinical-oncology-annual-meeting-commentary
#7
Susan M O'Brien
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30235179/highlights-in-chronic-lymphocytic-leukemia-from-the-2018-american-society-of-clinical-oncology-annual-meeting
#8
(no author information available yet)
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067623/bromodomain-inhibitors-what-does-the-future-hold
#9
Seemana Bhattacharya, Sujan Piya, Gautam Borthakur
Cancer cells are addicted to mutations that cause gain of function in oncogenes and loss of function in tumor suppressors, so that these cells are reliant on aberrant signaling pathways and transcription. Protein-protein and DNA-protein interactions that cause chromatin remodeling are another source of the deregulation of critical signaling and transcriptional regulators, altering epigenetic signatures and creating additional vulnerabilities. Owing to mutations in multiple epigenetic regulators in hematologic malignancies, cancer cells are highly addicted to altered transcription...
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067621/development-of-poly-adp-ribose-polymerase-inhibitors-in-the-treatment-of-brca-mutated-breast-cancer
#10
Nanna H Sulai, Antoinette R Tan
The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA. The use of PARP inhibitors is a rational therapeutic approach to selectively killing a subset of cancer cells with deficiencies in DNA repair pathways. PARP inhibitors that have undergone clinical investigation in the treatment of breast cancer include olaparib, talazoparib, veliparib, niraparib, and rucaparib. The antitumor activity of PARP inhibitors as single agents has been demonstrated in BRCA-associated metastatic breast cancer...
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067620/how-i-treat-breast-cancer-with-positive-lymph-nodes
#11
Anees B Chagpar
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067619/immunotherapy-in-patients-who-have-nsclc-without-egfr-or-alk-mutations
#12
Leena Gandhi
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067618/recent-and-ongoing-clinical-trials-in-glioblastoma
#13
Giuseppe Lombardi
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067617/new-and-experimental-agents-for-sickle-cell-disease
#14
Kenneth I Ataga
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067616/recent-insights-into-large-granular-lymphocytic-leukemia
#15
Loretta J Nastoupil
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067615/contemporary-management-of-advanced-renal-cell-carcinoma
#16
Abhinav Khanna, Alice Crane, Nitin Yerram, Daniel Sun, Kyle Ericson, Scott D Lundy, Robert Abouassaly
Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease at presentation. Historically, survival outcomes for patients with advanced disease have been poor. In recent years, several novel targeted agents have emerged for the management of advanced renal cell carcinoma that have changed treatment paradigms. At the same time, surgical therapy continues to have a critical role in the management of selected patients...
June 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067614/management-of-newly-diagnosed-or-recurrent-ovarian-cancer
#17
Ursula A Matulonis
The treatment of newly diagnosed or recurrent ovarian cancer has changed significantly in recent years, with an increased number of treatment options available. Surgery and combination treatment with carboplatin and paclitaxel are the standard of care for patients with newly diagnosed disease, although the use of neoadjuvant chemotherapy is increasing. Clinical strategies have also evolved along with the understanding that ovarian cancer is not one disease but rather comprises several with different histologic and underlying genetic characteristics...
June 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067613/highlights-in-kidney-cancer-from-the-american-society-of-clinical-oncology-genitourinary-cancers-symposium
#18
Robert A Figlin
No abstract text is available yet for this article.
June 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067612/cellular-immunotherapy-for-non-hodgkin-lymphoma
#19
Catherine Bollard
No abstract text is available yet for this article.
June 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30067611/a-closer-look-at-blinatumomab
#20
Ryan J Mattison
On March 29, 2018, blinatumomab (Blincyto, Amgen) received an accelerated expanded approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in first or second complete remission (CR) and have minimal residual disease (MRD). Blinatumomab was first approved for use in adult patients (in December 2014) and later in pediatric patients (in September 2016) with relapsed or refractory Philadelphia chromosome (Ph)-negative B-cell precursor ALL; the approval was expanded in July 2017 to include patients with Ph-positive disease...
June 2018: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"